Boston University

The University of British Columbia

British Columbia Cancer Agency Branch

University of Utah Research Foundation

Health Research, Inc.

Avrum Spira

Marc Elliott Lenburg

Joshua David Campbell

Jerome S Brody

Ana Brandusa Pavel

Jennifer E Beane-Ebel

Katrina Steiling

Stephen C-t Lam

James Cameron Hogg

Julie Erin Zeskind Gil

Dimitri Petchkovski

Marc Lenberg

Elizabeth Jeanne Becker

Anthony W O'Regan

Anna Tassinari

Jeffrey S Berman

Adam Gustafson

Darryl Andrew Knight

Mary E Reid

Andrea Bild

Sarah Mazzilli

Marc Lenburg

Joshua Campbell

The technology described herein is directed to methods and compositions for prognosis and treatment of respiratory disease, e.g., COPD.

Methods and compositions relating to lung function

The methods and assays described herein relate to detection, diagnosis, and treatment of lung cancer, e.g., by detecting the level of expression of certain miRNAs described herein and/or by therapeutically increasing the level of those miRNAs.

Methods relating to lung cancer

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis from a nasal epithelial cell sample. The methods of the invention provide far less invasive method with a superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, such as lung cancer.

Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells

The technology described herein is directed to methods of treating and diagnosing bronchial premalignant lesions, e.g. by determining the lesion subtype using one or more biomarkers described herein.

Methods related to bronchial premalignant lesion severity and progression

Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.

Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions

The present invention provides methods for diagnosis and prognosis of lung cancer using expression analysis of one or more groups of genes, and a combination of expression analysis with bronchoscopy. The methods of the invention provide far superior detection accuracy for lung cancer when compared to any other currently available method for lung cancer diagnostic or prognosis. The invention also provides methods of diagnosis and prognosis of other lung diseases, particularly in individuals who are exposed to air pollutants, such as cigarette or cigar smoke, smog, asbestos and the like air contaminants or pollutants.

Diagnostic for lung disorders using class prediction

The invention provides the identification of oncogenic pathways activated in cytologically normal airway cells of individuals having or at risk of having lung disease, as well as specific gene expression patterns (biomarkers) associated with pathway activation. These biomarkers and pathways may provide prognostic and/or diagnostic indicators in lung disease, e.g., lung cancer. Additionally, these pathways and biomarkers may provide therapeutic targets for the treatment of lung disease, as well as markers for the assessment of treatment efficacy.

Methods of identifying individuals at increased risk of lung cancer

A novel set of 98 genes expressed in the respiratory tract epithelium that serve as biomarkers for measuring chronic obstructive pulmonary disease (COPD) activity are provided. Methods of classifying the (COPD) status of a subject are provided. Systems for expression-based classification of COPD disease status are provided. Methods of treating COPD are also provided, among other things.

Methods and systems for monitoring, diagnosing, and treating chronic obstructive pulmonary disease

The invention described herein relates to methods of treating emphysema and COPD with a GHK tripeptide. The invention further relates to methods of determining the state of the lungs using biomarkers described herein.

Therapeutic agent for emphysema and COPD

Growing community of inventors

Newton, MA, United States of America

Avrum Spira